Krystal Biotech Inc (KRYS) — Cash Flow Reinvestment Rate

Latest as of June 2026: 2.16x

Krystal Biotech Inc (KRYS) has a Cash Flow Reinvestment Rate of 2.16x as of June 2026, reinvesting $161.58 Million (capex $3.56 Million plus investments $-158.02 Million) from operating cash flow of $74.79 Million. See KRYS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

2.16x
(Capex + Investments) / Operating CF

Total Reinvested

$161.58 Million
Capex + Investments

Operating Cash Flow

$74.79 Million
USD

Capital Expenditures

$3.56 Million
USD

Krystal Biotech Inc Cash Flow Reinvestment Rate (2024–2025)

Historical reinvestment intensity for Krystal Biotech Inc across 2 annual periods. For the full cash flow conversion analysis, see Krystal Biotech Inc cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Krystal Biotech Inc (2024–2025)

Year-by-year capital reinvestment analysis for Krystal Biotech Inc. See financial flexibility index of Krystal Biotech Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 0.29x $58.85 Million $200.87 Million $11.95 Million ▼ -78.4%
2024 1.36x $167.68 Million $123.42 Million $4.24 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow